Search

The article presents information about new developments related to the pharmaceutical industry. The U.S. Food and Drug Administration has approved UCB's Keppra for the treatment of myoclonic seizures and juvenile myoclonic epilepsy. A study has been launched by Adolor to test ADL5859, a Delta opioid receptor used for pain management. According to an independent data safety monitoring board's recommendation, YM BioSciences Inc. should continue the trial of its breast cancer drug tesmilifene.

The article reports on the acquisition of the exclusive worldwide rights to a opioid receptor antagonist, OpRA III, from Eli Lilly and Company by biopharmaceutical company Adolor Corp. It notes that Adolor plans to develop OpRA III as opioid bowel dysfunction treatment. The terms of agreement include an upfront payment of two million dollars to Lily, royalties on net sales, and 70 million dollars in milestones contingent.

The article offers news briefs related to the pharmaceutical industry in the U.S. A Delta opioid receptor capable of regulating pain and may be applied to other medical conditions was launched by Adolor Corp. after it has sought approval from the U.S. Food and Drug Administration. A settlement negotiation has been agreed between Teva Pharmaceutical Industries Ltd. and Purdue Pharma LP on its formulation patents.

The article reports that Adolor Corp. has submitted an investigational drug application with the U.S. Food and Drug Administration (FDA) for ADL5859, an oral compound for the management of pain. If FDA will approve the application, Adolor will be able to begin clinical testing of the compound. The drug is aimed for the delta opioid receptor, one of the three opioid receptors that modulate pain and may have application in other indications.